Immunotherapy for Relapsed or Refractory NSCLC – OncLive
OncLive |
Immunotherapy for Relapsed or Refractory NSCLC
OncLive Everett Vokes, MD: At the current state of affairs, where we have second-line immune therapies that we routinely give, for pembrolizumab, there's guidelines to look at PD-L1 expression. But for nivolumab and atezolizumab, those recommendations don't exist. |
